An observational study in HR+/HER2- Advanced or Metastatic Breast Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies in Breast Neoplasms by Novartis — 17 open to participants now, 31 under way, 4 of them phase 3. Breast Neoplasms · Novartis.
Among the 200 studies in Breast Neoplasms by Novartis, this one is the 2nd largest by planned enrollment of the 39 observational ones that give a count, is one of 11 that started in 2026, is one of 39 observational ones, reaches primary completion later than 7 of the 30 other live ones, and was the 190th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →17 of the 200 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, Japan
Ages 18+
Novartis Pharmaceuticals · Sites in Netherlands
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, France and 6 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Russia
Ages 18–90
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 54 · Phase 3 48 · Phase 4 17
First in 1998; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 104 across the 155 interventional studies, 595 across the 39 observational. Of the 160 that completed or were terminated, 74 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
11 of the studies in Breast Neoplasms by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05870579Novartis Pharmaceuticals[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | 2026-12-30 |
| NCT07945548Novartis PharmaceuticalsA Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning Approach With Real-world Data | 2027-01-01 |
| NCT04544189Novartis PharmaceuticalsStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | 2027-01-29 |
Add all 11 to your calendar (.ics) → With an account.
Among the 200 studies in Breast Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to fill the current gap in data regarding HR+/HER2- ABC 1L treatment patterns and outcomes in the real-world setting in China, especially in the context of the widespread application of CDK4/6is and the lack of sufficient evidence for ribociclib as a most recently marketed drug in the real-world setting.
This study is a longitudinal, non-interventional, retrospective, and observational study based on secondary real-world data in the National Anti-Tumor Drug Surveillance System (NATDSS) database. The study will not involve any active intervention, randomization, or control group.
All analyses will be conducted using Electronic Health Record (EHR) routinely collected in clinical practice and additional secondary data sources
HR+/HER2- ABC adult patients (aged 18 years or older) with 1L treatment being initiated between Jan. 1, 2024 and Jan. 1, 2027, and have at least 3 months of follow-up records after the initiation of 1L treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with HR+/- ABC:
HR+ is defined as ER+ or PR+, and HER2+ is defined as immunohistochemistry 3+, or 2+ with positive in situ hybridization (amplification). Advanced or breast cancer is defined as having a documented inoperable clinical or pathological stage IIIB, IIIC, or IV, or the records indicating distant metastasis.
Exclusion Criteria:
(1) Patients with any other concomitant invasive Defined as patients meeting any of the following conditions based on their diagnosis records in the cancer registry/medical database used for the study: 1. Within 5 years before the diagnosis of HR+/- ABC, there is a diagnosis record of invasive malignancy other than breast cancer in the database (based on the International Classification of Diseases [ICD] diagnosis code or cancer registry code), and the diagnosis is not carcinoma in situ or benign/borderline tumor; 2. On the day of, or within 3 months after, the diagnosis of HR+/HER2- ABC, there is a new diagnosis record of invasive malignancy at another site (also based on the ICD diagnosis code or cancer registry code) indicating a concomitant active malignancy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Distribution of first-line treatment regimens
Proportion of patients receiving each first line treatment category and specific regimen
Time frame: Up to 39 months
Proportion of patients with treatment changes
Proportion of patients who discontinue or switch first line treatment
Time frame: Up to 39 months
Time to treatment initiation, time to discontinuation, and time to next line therapy
Time to treatment initiation (TTI), time to discontinuation (TTD), and time to next-line therapy (TTNT)
Time frame: Up to 39 months
Proportion of patients by initial CDK4 6 inhibitor dose
Proportion of patients treated with a CDK4 6 inhibitor, stratified by initial dose level
Time frame: Up to 39 months
Proportion of patients with dose modifications of CDK4/6 inhibitor therapy
Proportion of patients treated with CDK4/6 inhibitor who experience any dose modification (including dose reduction and interruption)
Time frame: Up to 39 months
Time to first dose modification of CDK4/6 inhibitor therapy
Time from initiation of CDK4/6 inhibitor therapy to the first dose modification, including dose reduction or interruption
Time frame: Up to 39 months
rwPFS of 1L treatment patterns
rwPFS is defined as the duration from the initiation date of 1L treatment to documented disease progression or death from any cause. If a patient has not experienced disease progression or death, the last confirmed survival time will be used as the censoring time to calculate the rwPFS censoring duration
Time frame: Up to 39 months
rwPFS of HR+/HER2- ABC patients
rwPFS of HR+/HER2- ABC patients adhering or not adhering to the highest level of first-line treatment recommendation in the guidelines in the real-world setting based on the NATDSS database
Time frame: Up to 39 months
rwPFS of HR+/HER2- ABC patients receiving ribociclib-based 1L treatment regimens
rwPFS of HR+/HER2- ABC patients receiving ribociclib-based 1L treatment regimens in the real-world setting based on the NATDSS database
Time frame: Up to 39 months
Number of subjects with AESIs
AESIs under different treatment patterns, including: * Hematology: neutropenia, leukopenia, anemia, and thrombocytopenia; * Gastrointestinal tract: diarrhea, nausea, vomiting, stomatitis/mucositis; * QTc prolongation; * Hepatotoxicity: alanine transaminase (ALT)/aspartate transaminase (AST) increased, and total bilirubin increased.
Time frame: Up to 39 months
Baseline demographics
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.